Aeterna Zentaris Inc AEZS Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125

08:35 EDT 21 Aug 2017 | BioPortfolio Reports

Aeterna Zentaris Inc AEZS Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description A detailed description of the company's operations and business divisions.
Corporate strategy Analyst's summarization of the company's business strategy.
SWOT Analysis A detailed analysis of the company's strengths, weakness, opportunities and threats.
Company history Progression of key events associated with the company.
Major products and services A list of major products, services and brands of the company.
Key competitors A list of key competitors to the company.
Key employees A list of the key executives of the company.
Executive biographies A brief summary of the executives' employment history.
Key operational heads A list of personnel heading key departments/functions.
Important locations and subsidiaries A list and contact details of key locations and subsidiaries of the company.
Key manufacturing facilities A list of key manufacturing facilities of the company.
Detailed financial ratios for the past five years The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods The latest financial ratios derived from the quarterly/semiannual financial statements published by the company for 5 interims history.


Aeterna Zentaris Inc Aeterna Zentaris is a specialty biopharmaceutical company which develops and commercializes therapies for the treatment of cancer, endocrine disorders and infectious diseases. The pipeline products of the company are aimed at the treatment of various kinds of cancers including endometrial, ovarian and prostate. The company submitted New Drug Application to the FDA for its lead product, Macrilen macimorelin formery AEZS130, for the evaluation of adult growth hormone deficiency AGHD. Some of the other pipeline products of the company include Zoptrex Zoptarelin doxorubicin, AEZS120, and LHRHDisorazol Z conjugate AEZS138. Aeterna Zentaris is headquartered in Quebec, Canada.

Aeterna Zentaris Inc Key Recent Developments

Jul 20,2017: Aeterna Zentaris appoints Michael Ward as CEO
Jul 20,2017: Aeterna Zentaris Forms Strategic Review Committee and Appoints Michael Ward as CEO
May 08,2017: Aeterna Zentaris Reports First Quarter 2017 Financial and Operating Results
Mar 15,2017: Aeterna Zentaris Reports Fourth Quarter and FullYear 2016 Financial and Operating Results
Nov 08,2016: Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Original Article: Aeterna Zentaris Inc AEZS Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125


More From BioPortfolio on "Aeterna Zentaris Inc AEZS Financial and Strategic SWOT Analysis Review [Report Updated: 25072017] Prices from USD $125"

Quick Search


Relevant Topics

  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Endocrine Disorders
Endocrine disorders are grouped into two categories: hormone imbalance - when a gland produces too much or too little of an endocrine hormone development of lesions (such as nodules or tumors) in the endocrine system, which may or may not affect...